Teknova CFO Reiterates 2026 Revenue Guidance of $42-44 Million
Matt Lowell, Teknova's Chief Financial Officer, added, "We delivered strong financial results in the first quarter 2026 compared to 2025, including 13% revenue growth and significant improvements in Adjusted EBITDA and Free Cash Outflow. We believe the Company is well positioned to maintain its momentum. We therefore reiterate our 2026 revenue guidance of $42-44 million and continue to anticipate full-year Free Cash Outflow of less than $10 million," he explained.
Trade with 70% Backtested Accuracy
Analyst Views on TKNO
About TKNO
About the author
Alpha Teknova Reports Q4 Loss with Revenue Growth
- Financial Overview: Alpha Teknova reported a fourth-quarter loss of $4.76 million, translating to a loss of $0.09 per share, which is an improvement from last year's loss of $5.72 million or $0.11 per share, indicating gradual financial recovery.
- Revenue Growth: The company achieved fourth-quarter revenue of $9.98 million, a 7.7% increase from $9.27 million last year, reflecting enhanced sales capabilities amid recovering market demand, potentially laying the groundwork for future profitability.
- Year-over-Year Comparison: Although still in a loss position, Alpha Teknova's reduced loss compared to last year suggests progress in cost control and operational efficiency, which may attract investor interest.
- Market Outlook: With revenue growth and reduced losses, Alpha Teknova is positioned for improved financial performance in upcoming quarters, enhancing its competitiveness and market confidence in the biotechnology sector.
Alpha Teknova Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: In Q4 2025, Alpha Teknova reported total revenue of $10 million, a 7% increase from $9.3 million in Q4 2024, indicating sustained competitiveness in the market and potential for future business expansion.
- Expanded Customer Base: The number of active customers purchasing clinical products rose to 60, a 25% increase from 2024, which not only enhances market share but also lays a solid foundation for future revenue growth.
- Improved Gross Margin: The gross margin for Q4 2025 was 32.5%, up from 23.0% in Q4 2024, reflecting successful cost control and pricing strategies, which are expected to further enhance profitability.
- Optimistic Future Outlook: Management projects total revenue guidance for 2026 to be between $42 million and $44 million, implying approximately 6% growth at the midpoint, demonstrating confidence in future market opportunities, particularly in the commercialization of new therapies.
Alpha Teknova Q4 Earnings Exceed Expectations
- Earnings Beat: Alpha Teknova reported a Q4 GAAP EPS of $0.09, surpassing expectations by $0.18, indicating a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $10 million, reflecting a 7.5% year-over-year increase and exceeding expectations by $0.39 million, demonstrating its sustained competitiveness in the market, which may attract more investor interest.
- Positive Market Reaction: Given the strong earnings report, Alpha Teknova's stock price is likely to experience a positive impact, further enhancing the company's market position in the biotechnology sector and drawing attention from institutional investors.
- Optimistic Outlook: With ongoing operational optimizations and product line enhancements, the company is expected to maintain growth momentum in the coming quarters, solidifying its leadership position in the industry.
Alpha Teknova (TKNO) Third Quarter 2025 Earnings Call Transcript
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
IMRX Rises on Pancreatic Cancer Findings, PEPG Achieves DM1 Splicing Correction Milestone, CLPT Under Observation
Biotech Stock Performance: Several biotech stocks, including PepGen and Immuneering, experienced significant gains due to positive clinical trial results, with PepGen's stock soaring 36% during regular trading and an additional 134% in after-hours trading following promising data for its myotonic dystrophy treatment.
Clinical Trial Updates: Immuneering reported an impressive overall survival rate of 86% in its pancreatic cancer trial, while other companies like Clearmind Medicine and Jasper Therapeutics also saw stock increases based on ongoing clinical evaluations and positive preliminary results.
Market Developments: ClearPoint Neuro's stock surged over 58% after receiving FDA clearance for its laser therapy system, expanding its market potential, while Neuphoria Therapeutics anticipates topline results from its social anxiety disorder trial in early Q4 2025.
Investor Interest: The overall investor interest in biotech stocks is reflected in the significant price movements of various companies, driven by clinical trial advancements and strategic opportunities, indicating a robust market for biotech innovations.
Experts Forecast Potential 840% Surge for These 2 'Strong Buy' Penny Stocks
Penny Stocks vs. Mega-Cap Stocks: While large companies like Nvidia dominate the stock market, penny stocks (priced below $5) offer significant growth potential, with the possibility of triple-digit percentage gains, though investors must be cautious due to inherent risks.
Highlighted Penny Stocks: Two penny stocks, Protara Therapeutics (TARA) and Alpha Teknova (TKNO), have received strong buy ratings from analysts, with TARA showing potential for an 840% increase and TKNO for a 159% increase, driven by promising clinical developments and market positioning.
Alpha Teknova Reports Q4 Loss with Revenue Growth
- Financial Overview: Alpha Teknova reported a fourth-quarter loss of $4.76 million, translating to a loss of $0.09 per share, which is an improvement from last year's loss of $5.72 million or $0.11 per share, indicating gradual financial recovery.
- Revenue Growth: The company achieved fourth-quarter revenue of $9.98 million, a 7.7% increase from $9.27 million last year, reflecting enhanced sales capabilities amid recovering market demand, potentially laying the groundwork for future profitability.
- Year-over-Year Comparison: Although still in a loss position, Alpha Teknova's reduced loss compared to last year suggests progress in cost control and operational efficiency, which may attract investor interest.
- Market Outlook: With revenue growth and reduced losses, Alpha Teknova is positioned for improved financial performance in upcoming quarters, enhancing its competitiveness and market confidence in the biotechnology sector.
Alpha Teknova Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: In Q4 2025, Alpha Teknova reported total revenue of $10 million, a 7% increase from $9.3 million in Q4 2024, indicating sustained competitiveness in the market and potential for future business expansion.
- Expanded Customer Base: The number of active customers purchasing clinical products rose to 60, a 25% increase from 2024, which not only enhances market share but also lays a solid foundation for future revenue growth.
- Improved Gross Margin: The gross margin for Q4 2025 was 32.5%, up from 23.0% in Q4 2024, reflecting successful cost control and pricing strategies, which are expected to further enhance profitability.
- Optimistic Future Outlook: Management projects total revenue guidance for 2026 to be between $42 million and $44 million, implying approximately 6% growth at the midpoint, demonstrating confidence in future market opportunities, particularly in the commercialization of new therapies.
Alpha Teknova Q4 Earnings Exceed Expectations
- Earnings Beat: Alpha Teknova reported a Q4 GAAP EPS of $0.09, surpassing expectations by $0.18, indicating a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $10 million, reflecting a 7.5% year-over-year increase and exceeding expectations by $0.39 million, demonstrating its sustained competitiveness in the market, which may attract more investor interest.
- Positive Market Reaction: Given the strong earnings report, Alpha Teknova's stock price is likely to experience a positive impact, further enhancing the company's market position in the biotechnology sector and drawing attention from institutional investors.
- Optimistic Outlook: With ongoing operational optimizations and product line enhancements, the company is expected to maintain growth momentum in the coming quarters, solidifying its leadership position in the industry.
Alpha Teknova (TKNO) Third Quarter 2025 Earnings Call Transcript
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
IMRX Rises on Pancreatic Cancer Findings, PEPG Achieves DM1 Splicing Correction Milestone, CLPT Under Observation
Biotech Stock Performance: Several biotech stocks, including PepGen and Immuneering, experienced significant gains due to positive clinical trial results, with PepGen's stock soaring 36% during regular trading and an additional 134% in after-hours trading following promising data for its myotonic dystrophy treatment.
Clinical Trial Updates: Immuneering reported an impressive overall survival rate of 86% in its pancreatic cancer trial, while other companies like Clearmind Medicine and Jasper Therapeutics also saw stock increases based on ongoing clinical evaluations and positive preliminary results.
Market Developments: ClearPoint Neuro's stock surged over 58% after receiving FDA clearance for its laser therapy system, expanding its market potential, while Neuphoria Therapeutics anticipates topline results from its social anxiety disorder trial in early Q4 2025.
Investor Interest: The overall investor interest in biotech stocks is reflected in the significant price movements of various companies, driven by clinical trial advancements and strategic opportunities, indicating a robust market for biotech innovations.
Experts Forecast Potential 840% Surge for These 2 'Strong Buy' Penny Stocks
Penny Stocks vs. Mega-Cap Stocks: While large companies like Nvidia dominate the stock market, penny stocks (priced below $5) offer significant growth potential, with the possibility of triple-digit percentage gains, though investors must be cautious due to inherent risks.
Highlighted Penny Stocks: Two penny stocks, Protara Therapeutics (TARA) and Alpha Teknova (TKNO), have received strong buy ratings from analysts, with TARA showing potential for an 840% increase and TKNO for a 159% increase, driven by promising clinical developments and market positioning.
